Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice

Journal of Inflammation (United Kingdom)

Volumn 11, Issue 1, 2014, Pages

  Majhi, Arnab ^a   Kundu, Kiran ^b   Adhikary, Rana ^a   Banerjee, Madhubanti ^a   Mahanti, Sayantika ^a   Basu, Anirban ^b   Bishayi, Biswadev ^a  

^a UNIVERSITY OF CALCUTTA   (India)

^b NATIONAL BRAIN RESEARCH CENTRE   (India)

Author keywords

Ampicillin; Azihromycin; Combination therapy; Inflammation; Multiple drug resistance; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOOXYGENASE 2; GAMMA INTERFERON; GENTAMICIN; IMIPENEM; INTERLEUKIN 10; INTERLEUKIN 6; LEVOFLOXACIN; MEROPENEM; MYELOPEROXIDASE; OXACILLIN; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; BLOOD VESSEL PERMEABILITY; CELL COUNT; CONTROLLED STUDY; DOWN REGULATION; DRUG HALF LIFE; EXPERIMENTAL PNEUMOCOCCAL PNEUMONIA; HISTOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; LUNG LAVAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMONIA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 84895462067     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-11-5     Document Type: Article

References (69)

1. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Aspa J, Rajas O, de Castro FR, Expert Opin Pharmacothe 2008 9 229 241 10.1517/14656566.9.2.229
2. T-regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. Neill DR, Fernandes VE, Wisby L, Haynes AR, Ferreira DM, Laher A, Strickland N, Gordon SB, Denny P, Kadioglu A, Andrew PW, Plos Pathogens 2012 8 1 12
3. The preventable burden of pneumococcal disease in the developing world. Scott JAG, Vaccine 2007 25 2398 2405 10.1016/j.vaccine.2006.09.008 17028081
4. Molecular epidemiological survey of penicillin resistant Streptococcus pneumoniae from Asia, Europe and North America. Davies T, Goering RV, Lovgren M, Talbot JA, Jacobs MR, Appelbaum PC, Diagn Microbiol Infect Dis 1999 34 7 12 10.1016/S0732-8893(98)00156-4 10342101
5. Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. Tomasz A, Corso A, Severina EP, Echaniz-Aviles G, Brandileone MC, Camou T, Castaneda E, Figueroa O, Rossi A, Di Fabio JL, PAHO/Rockefeller University Workshop, Pan American Health Organization Microbial Drug Resistance 1998 4 195 207
6. Reporting emerging resistance of Streptococcus pneumoniae from India. Chawla K, Gurung B, Mukhopadhyay C, Bairy I, J Glob Infect Dis 2010 2 10 14 10.4103/0974-777X.59245 20300412
7. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN, Clin Infect Dis 1998 27 764 770 10.1086/514953 9798031
8. A multicentre study of the antimicrobial susceptibility of community acquired lower respiratory tract pathogens in the United States, 1992-1994. Washington J, Alexander Project Group, Diagn Microbiol Infect Dis 1996 25 183 190 10.1016/S0732-8893(96)00128-9 8937842
9. Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community acquired pneumonia. Jenkins TC, Sakai J, Kneppe BC, Swartwood CJ, Haukoos JS, Long JA, Price CS, Burman WJ, Acad Emerg Med 2012 19 703 706 10.1111/j.1553-2712.2012.01365.x 22632455
10. Guidelines for community-acquired pneumonia: are they reflected in practice? Flanders SA, Halm EA, Treatment Respiratory Medicine 2004 3 67 77 10.2165/00151829-200403020-00001
11. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Niederman MS, Bass JB, Campbell GD, Fein AM, Grossman RF, Mandell LA, Marrie TJ, Sarosi GA, Torres A, Yu VL, Am Rev Respi Dis 1993 148 1418 1426 10.1164/ajrccm/148.5.1418
12. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society, Am J Respir Crit Care Med 2001 163 1730 1754 10.1164/ajrccm.163.7.at1010 11401897
13. Community-acquired pneumonia in adults: guidelines for management, The Infectious Disease Society of America. Bartlett JG, Breiman RF, Mandell LA, File TM Jr, Clin Infect Dis 1998 26 811 838 10.1086/513953 9564457
14. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C, Infectious Diseases Society of America, Clin Infect Dis 2003 37 1405 1433 10.1086/380488 14614663
15. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Waterer GW, Somes GW, Wunderink RG, Arch Intern Med 2001 161 1837 1842 10.1001/archinte.161.15.1837 11493124
16. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J, Clin Infect Dis 2003 36 389 395 10.1086/367541 12567294
17. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacterimia. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC, International Pneumococcal Study Group, Am J Respir Crit Care Med 2004 170 440 444 10.1164/rccm.200311-1578OC 15184200
18. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Brown RB, Iannini P, Gross P, Kunkel M, Chest 2003 123 1503 1511 10.1378/chest.123.5. 1503 12740267
19. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, Legare M, Nepveu F, Thibert D, Tremblay C, Tremblay J, Can Respir J 2004 11 589 593 15611810
20. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Garcia-Vazquez E, Mensa J, Martinez JA, Marcos MA, Puig J, Ortega M, Torres A, Eur J Clin Microbiol Infect Dis 2005 24 190 195 10.1007/s10096-005-1295-9 15782278
21. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Metersky ML, Ma A, Houck PM, Bratzler DW, Chest 2007 131 466 473 10.1378/chest.06-1426 17296649
22. A stepwise approach to management of stable COPD with inhaled pharmacotherapy: a review. Restrepo RD, Respiratory Care 2009 54 1058 1081 19650947
23. Impact of intravenous {beta}-lactam/macrolide versus beta-lactam monotherapy on mortality in hospitalized patients with community acquired pneumonia. Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N, J Antimicrob Chemother 2009 63 1025 1033 10.1093/jac/dkp088 19293196
24. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community acquired pneumonia. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP, Antimicrob Agents Chemother 2007 51 3977 3982 10.1128/AAC.00006-07 17709460
25. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia. Todisco T, Dal Farra F, Ciliberti G, Pirina P, Guelfi R, Serra G, Paris R, Mancuso I, Cepparulo M, J Chemother 2008 20 225 232 10.1179/joc.2008.20.2.225 18467250
26. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Nau R, Eiffert H, Clin Microbiol Rev 2002 15 95 110 10.1128/CMR.15.1.95-110.2002 11781269
27. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Tuomanen E, Rich R, Zak O, Am Rev Respir Dis 1987 135 869 874 3565933
28. Effect of antiviral treatment in the outcome of secondary bacterial pneumonia after influenza. McCullers JA, J Infect Dis 2004 190 519 526 10.1086/421525 15243927
29. Toll like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. Karlstrom A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA, J Infect Dis 2011 204 1358 1366 10.1093/infdis/jir522 21900488
30. Comparative evaluation of synergy of combinations of β-lactams with fluoroquinolones or a macrolide in Streptococcus pneumonia. Drago L, Nicola L, Rodighiero V, Larosa M, Mattina R, De Vecchi E, J Antimicrob Chemother 2011 66 845 849 10.1093/jac/dkr016 21393187
31. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Mc Cool TL, Weiser JN, Infection Immunity 2004 72 5807 5813 10.1128/IAI.72.10.5807-5813.2004 15385481
32. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. CLSI, Wayne: Clinical and Laboratory Standards Institute 7 2006 7 A7
33. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI, Wayne: Clinical and Laboratory Standards Institute 2008 100 S118
34. Streptococcus pneumoniae causes experimental meningitis following intranasal and otitis media infections via a non hematogenous route. Marra A, Brigham D, Infection Immunity 2001 69 7318 7325 10.1128/IAI.69.12.7318-7325.2001 11705903
35. Activities of garenoxacin against quinolone resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Azoulay-Dupuis E, Bedos JP, Mohler J, Peytavin G, Isturiz R, Moine P, Rieux V, Cherbuliez C, Pechere JC, Fantin B, Kohler T, Antimicrob Agents Chemother 2004 48 765 773 10.1128/AAC.48.3.765-773.2004 14982762
36. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. Peterson LR, Gerding DN, Rev Infect Dis 1980 2 340 348 10.1093/clinids/2.3.340 6997964
37. Penicillin pharmacodynamics in four experimental pneumococcal infection models. Erlendsdottir H, Knudsen JD, Odenholt I, Cars O, Espersen F, Frimodt-Moller N, Fuursted K, Kristinsson KG, Gudmundsson S, Antimicrob Agents Chemother 2001 45 1078 1085 10.1128/AAC.45.4.1078-1085.2001 11257018
38. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M, Bergeron MG, Infection Immunity 1998 66 912 922 9488375
39. Transvascular flux and tissue accrual of Evans blue: effects of endotoxin and histamine. Green TP, Johnson DE, Marchessault RP, Gatto CW, J Lab Clin Med 1988 111 73 83 3335827
40. Increased resistance of immobilized-stressed mice to infection: correlation with behavioral alterations. Mahanti S, Majhi A, Chongder S, Kundu K, Dutta K, Basu A, Bishayi B, Brain Behav Immun 2013 28 115 127 23142705
41. Kinetic study of the inflammatory response in S. pneumonia experimental pneumonia treated with the ketolide HMR 3004. Duong M, Simard M, Bergeron Y, Bergeron MG, Antimicrob Agents Chemother 2001 45 252 262 10.1128/AAC.45.1.252- 262.2001 11120974
42. Molecular pathogenesis of pneumococcal pneumonia. McCullers JA, Tuomanen EI, Frontiers Bioscience 2001 6 877 D889 10.2741/McCullers
43. Effects of antibiotic class on the macrophage inflammatory response to Streptococcus pneumoniae. Orman KL, English BK, J Infect Dis 2000 182 1561 1565 10.1086/315861 11023483
44. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. faropenem surveillance study. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N, Antimicrob Agents Chemother 2007 51 4382 4389 10.1128/AAC.00971-07 17908940
45. Immunomodulation by macrolide antibiotics. Labro MT, Abdelghaffar H, J Chemother 2001 13 3 8 10.1179/joc.2001.13.1.3 11233797
46. Anti-inflammatory activity of macrolide antibiotics. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Luvone T, J Pharmacol Exp Ther 2000 292 156 163 10604943
47. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Morikawa K, Watabe H, Araake M, J Antimicrobial Agents Chemotherapy 1996 40 1366 1370
48. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Cigana C, Assael BM, Melotti P, Antimicrob Agents Chemother 2007 51 975 981 10.1128/AAC.01142-06 17210769
49. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. Karlström A, Boyd KL, English BK, McCullers JA, J Infect Dis 2009 199 311 319 10.1086/596051 19113989
50. Beneficial and harmful interactions of antibiotics with microbial pathogens and the host innate immune system. Anderson R, Tintinger G, Cockeran R, Potjo M, Feldman C, Pharmaceuticals 2010 3 1694 1710 10.3390/ph3051694
51. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Ivetic V, Tkalcevic, Bosnjak B, Hrvacic B, Bosnar M, Marjanovic N, Ferencic Z, Situm K, Culic O, Parnham MJ, Erakovic V, Eur J Pharmacol 2006 539 131 138 10.1016/j.ejphar.2006.03.074 16698012
52. Interpretation of middle ear fluid concentration of antibiotics: comparison between ceftibuten, cefixime and azithromycin. Scaglione F, Demartini G, Dugnani S, Arcidiacono MM, Pintucci JP, Fraschini F, Br J Clin Pharmacol 1998 47 267 271
53. Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin resistant Streptococcus pneumoniae. Barry B, Muffat-Joly M, Gehanno P, Pocidalo JJ, Antimicrob Agents Chemother 1993 37 1599 1603 10.1128/AAC.37.8.1599 8215269
54. Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Gustafsson I, Löwdin E, Odenholt I, Cars O, Antimicrob Agents Chemother 2001 45 2436 2440 10.1128/AAC.45.9.2436-2440.2001 11502511
55. Immunomodulating activity of quinolones: review. Riesbeck K, J Chemother 2002 14 3 12 10.1179/joc.2002.14.1.3 11892896
56. Roles of interleukin-6 and macrophage inflammatory protein-2 in pneumolysin induced lung inflammation in mice. Rijneveld AW, van den Dobbelsteen GP, Florquin S, Standiford TJ, Speelman P, van Alphen L, van der Poll T, J Infect Dis 2002 185 123 126 10.1086/338008 11756992
57. The acute respiratory distress syndrome. Ware LB, Matthay MA, N Engl J Med 2000 342 1334 1339 10.1056/NEJM200005043421806 10793167
58. Platelet-neutrophil interactions: Linking hemostasis and inflammation. Zarbock A, Polanowska-Grabowska RK, Ley K, Blood Reviews 2007 21 99 111 10.1016/j.blre.2006.06.001 16987572
59. A2B adenosine receptor dampens hypoxia-induced vascular leak. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschiq HK, Blood 2008 111 2024 2035 10.1182/blood-2007-10-117044 18056839
60. Critical role of endothelial CXCR-2 in LPS induced neutrophil migration into the lung. Reutershan J, Morris MA, Burcin TL, Smith DF, Chang D, Saprito MS, Ley K, J Clin Invest 2006 116 695 702 10.1172/JCI27009 16485040
61. Interleukin-6 in bacterial infection and sepsis: innocent bystander or essential mediator? van der Poll T, Deventer SJH, Yearbook of intensive care and emergency medicine Berlin: Springer Verlag, Vincent JL, 1999 43 53
62. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Khan AA, Slifer T, Araujo FG, Int J Antimicrob Agents 1999 11 121 132 10.1016/S0924-8579(98)00091-0 10221415
63. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous infection model. Kutlin A, Roblin PM, Hammerschlag MR, Antimicrob Agents Chemother 2002 46 409 412 10.1128/AAC.46.2.409-412.2002 11796350
64. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Donelly SC, Strieter RM, Reid PT, Annual International Medicine 1996 125 191 196 10.7326/0003-4819-125-3- 199608010-00005
65. IL-10: the master regulator of immunity to infection. Couper KN, Blount DG, Riley EM, J Immunol 2008 180 5771 5777 18424693
66. Modulation of cytokines and chemokines, limited pulmonary vascular bed permeability, and prevention of septicemia and death with ceftriaxone and interleukin-10 in pneumococcal pneumonia. Wang E, Simard M, Ouellet N, Bergeron Y, Beauchamp D, Bergeron MG, J Infect Dis 2000 182 1255 1299 10.1086/315811 10979929
67. Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia. Wang E, Bergeron Y, Bergeron MG, J Antimicrob Chemother 2005 55 721 726 10.1093/jac/dki085 15772139
68. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. van der Poll T, Keogh CV, Goldman M, Lowry SF, J Infect Dis 1996 174 994 1000 10.1093/infdis/174.5.994 8896500
69. Priming innate immune responses to infection by cyclooxygenease inhibition kills antibiotic susceptible and resistant bacteria. Stables MJ, Newson J, Ayoub SS, Brown J, Hyams CJ, Gilroy DW, Blood 2010 116 2950 2959 10.1182/blood-2010-05-284844 20606163